Track market-moving stories before they get noisy

Public event brings together a radiologist, urologist and robotic surgeon, and a prostate cancer survivor for an informative conversation and live Q&A about prostate cancer screening, diagnosis and treatment  | Source: RadNet, Inc.

LOS ANGELES, Sept. 09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 442 outpatient imaging centers and a premier developer of radiology digital health solutions, today announced it will host a free webinar for patients and the general public on Saturday, September 19, 2026, in support of Prostate Cancer Awareness Month.

Titled “Let’s Talk About It: Prostate Cancer: Your Questions Answered,” the webinar brings together a radiologist, urologist and robotic surgeon, and a prostate cancer survivor for a candid discussion about prostate cancer risk, screening, diagnosis, treatment and life after cancer. Attendees will also have the opportunity to submit questions during a live question-and-answer session.

Besides skin cancer, prostate cancer is the most commonly diagnosed cancer among American men. Approximately one in eight men will be diagnosed during his lifetime, and an estimated 333,830 new cases will be diagnosed in the United States in 2026.1 Although prostate and breast cancer have similar incidence and mortality rates in the United States, only 37% of men age 50 and older reported having a PSA test in the past year, compared with 80% of women ages 50 to 74 who were up to date with mammography.2 Age, family history and certain inherited genetic variants can increase a man’s risk of prostate cancer. For men with a strong family history, including two or more first-degree relatives diagnosed with prostate cancer, the relative risk may be four times higher.3

The September 19th webinar will help patients and families better understand these risks, what may happen following an elevated prostate-specific antigen (PSA) test and how advances in prostate MRI and other imaging technologies are informing diagnosis and treatment planning. The webinar also will explore how prostate MRI can help physicians identify suspicious areas that may require further evaluation and support more targeted biopsy decisions for patients with elevated PSA levels.4

The panelists include:

Robert Princenthal, MD, Medical Director of Prostate Imaging at RadNet, will discuss the importance of early detection, the role of prostate MRI and other imaging tools beyond the PSA test and recent advances in MRI, artificial intelligence and prostate cancer imaging.David Josephson, MD, urologist and robotic surgeon at Tower Urology in Los Angeles, will explain what patients can expect after an elevated PSA result and how physicians evaluate treatment options, from active surveillance to surgery and other therapies. He will also address prostate health at different ages, including risk factors, family history and genetics, and when men should begin speaking with their physicians about screening.Barry Katz, prostate cancer survivor, will share his personal experience, including how RadNet’s Enhanced Prostate Screening, which combines prostate MRI with AI, helped detect his cancer. He will also discuss the lessons he learned along the way and his advice for men and families navigating prostate cancer. “Too often, men wait until there is a concern to start thinking about prostate health,” said Robert Princenthal, MD, Medical Director of Prostate Imaging, RadNet. “By making information more accessible, we can help men ask the right questions sooner and better understand when it is time to take action. My hope is that everyone who joins us leaves more confident about their next steps and is motivated to start more conversations about prostate health."

Event Details
The webinar is free to attend and open to all.

Date: Saturday, September 19, 2026Time: 10-11 a.m. PDT // 1-2 p.m. EDTRegister: www.radnet.com/webinar About RadNet, Inc. 
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 12,000 team members. Learn more at radnet.com. 

These presentations are provided for educational and informational purposes only and do not constitute medical advice, diagnosis or treatment recommendations. Clinical decisions should be based on the independent judgment of qualified healthcare professionals, taking into account the specific circumstances of each patient.

RadNet Media Contact 
Jane Mazur 
Senior Vice President, Corporate Communications 
+1 585-355-5978 
[email protected]

References

“Key Statistics for Prostate Cancer.” American Cancer Society. January 2026, https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html.“Cancer Prevention & Early Detection Facts & Figures 2025-2026.” American Cancer Society. 2025, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-prevention-and-early-detection-facts-and-figures/2025-cped-files/cped-cff-2025-2026.pdf.Wei JT, et al., “Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.” The Journal of Urology. October 2023, https://www.auajournals.org/doi/10.1097/JU.0000000000003491.“Prostate Cancer Screening (PDQ®)–Health Professional Version.” National Cancer Institute. April 2025, https://www.cancer.gov/types/prostate/hp/prostate-screening-pdq.

RadNet.com

 | Source: RadNet, Inc.

LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Greg Sorensen, Executive Vice President and Chief Strategy Officer, will be presenting at the Jefferies Healthcare Services Conference on Tuesday, September 15, 2026 at 9:10 a.m. Central Time (7:10 a.m. Pacific Time).

There will be simultaneous and archived webcasts available at https://event.summitcast.com/view/GhCtEPrzrHFSChRnGR9UnE/guest_book?session_id=PK8GBUVgEotukZALpWAGno and www.radnet.com under the “About RadNet'' menu section and “News and Press Releases'' sub-menu of the website.

Details for RadNet's Presentation:
Date:Tuesday, September 15, 2026Time:9:10 a.m. Central Time (7:10 a.m. Pacific Time)Location:Nashville, TN  About RadNet, Inc.

RadNet RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit http://www.radnet.com.

Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2928

Oncology Institute (NASDAQ:TOI – Get Free Report) and RadNet (NASDAQ:RDNT – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Analyst Ratings This is a summary of current ratings and target prices for Oncology Institute and RadNet, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncology Institute 1 0 4 0 2.60 RadNet 1 1 5 2 2.89 Oncology Institute presently has a consensus price target of $8.50, indicating a potential upside of 63.90%. RadNet has a consensus price target of $88.00, indicating a potential upside of 14.55%. Given Oncology Institute’s higher probable upside, equities research analysts plainly believe Oncology Institute is more favorable than RadNet.

Valuation and Earnings This table compares Oncology Institute and RadNet”s top-line revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncology Institute $545.76 million 0.94 -$60.61 million ($0.37) -14.02 RadNet $2.04 billion 2.96 -$18.65 million ($0.27) -284.52 RadNet has higher revenue and earnings than Oncology Institute. RadNet is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility Oncology Institute has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, RadNet has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.

Insider & Institutional Ownership 36.9% of Oncology Institute shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 4.4% of Oncology Institute shares are held by insiders. Comparatively, 5.1% of RadNet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability This table compares Oncology Institute and RadNet’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Oncology Institute -7.42% N/A -24.68% RadNet -0.93% 2.61% 0.91% Summary RadNet beats Oncology Institute on 13 of the 15 factors compared between the two stocks.

(Get Free Report)

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

About RadNet (Get Free Report)

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways RadNet's Q2 revenues rose 25% to $622.7 million as advanced imaging volumes and Digital Health expanded.RDNT's Digital Health revenues jumped 56.5%, while ARR surged 97% year over year to $105.5 million.RadNet raised 2026 Imaging Center revenue and EBITDA guidance while maintaining its Digital Health outlook. RadNet, Inc. (RDNT - Free Report) reported second-quarter 2026 adjusted earnings of 29 cents per share, down 14.7% year over year but ahead of the Zacks Consensus Estimate of 18 cents by 61.1%.

GAAP EPS was 10 cents compared with 19 cents in the prior-year period.

Growth was led by stronger advanced imaging volumes, recent acquisitions and Digital Health expansion. Annual recurring revenues, or ARR, in Digital Health reached $105.5 million, up 97% year over year.

Revenue DetailsRevenues rose 25% to $622.7 million, topping the consensus mark by 1.4%.

RadNet’s share price improvement of 8.3% so far this year has underperformed the industry’s 20.5% increase as well as the S&P 500 Index’s 13.1% gain.

Image Source: Zacks Investment Research

The company reports under two segments — Advanced Imaging and Digital Health.

RDNT's Advanced Imaging Mix Strengthens

Advanced Imaging remained a major growth engine. Aggregate MRI volume increased 21%, CT volume rose 20.9% and PET/CT volume climbed 31% from the prior-year quarter’s level. Same-center MRI, CT and PET/CT volumes advanced 10.2%, 8.6% and 8.8%, respectively.

The mix also shifted toward higher-value modalities. Advanced imaging represented 29.9% of total procedural volume, up from 27.5% a year earlier. Management said prostate PSMA and brain amyloid studies accounted for more than 25% of PET/CT volume, while faster MRI scanners, extended operating hours and Tech Live remote technologists helped expand capacity.

RadNet's Digital Health Momentum Builds

Digital Health revenues surged 56.5% year over year to $32.4 million. AI revenues more than doubled to $16.1 million, while Enterprise Imaging revenues increased 17.3% to $16.3 million. External customers represented 63% of the segment's ARR base at quarter-end.

The company closed about $21 million of total contract value in the quarter, bringing first-half bookings to roughly $37 million. Its clinical AI and enterprise imaging pipeline expanded to more than $224 million of total contract value from about $101 million at the start of 2026. Management continues to target more than $140 million of ARR by year-end.

RDNT's Margin Gains Face Labor CostsOperating income totaled $39.47 million, up 27.8% from $30.88 million in the prior-year quarter. The operating margin improved roughly 14 basis points to 6.3% from 6.2% a year earlier.

Imaging Center adjusted EBITDA margin improved 17 basis points year over year to 16.1%. The favorable procedure mix and operating efficiencies aided profitability, though management continued to cite salary pressure from shortages of technologists and radiologists.

Total company adjusted EBITDA reached a quarterly record of $99.66 million, up 22.7% year over year. Digital Health adjusted EBITDA was $2.5 million compared with $3.4 million a year earlier, reflecting continued commercial, service and implementation investments as well as temporary acquisition-related margin dilution.

RDNT's Balance Sheet Supports ExpansionRadNet ended June with $726.3 million in cash and cash equivalents, up from $455.3 million in the first quarter. Cumulative net cash provided by operating activities at the end of the second quarter was $173.1 million compared with $55 million in the prior-year period.

The company completed a June debt repricing and funded a $250 million incremental term loan. Quarter-end net debt was $616.4 million, and the net debt-to-adjusted EBITDA ratio was 1.8 times. Management plans to use its liquidity for acquisitions, organic expansion and health-system partnerships.

RadNet Raises 2026 Imaging Center OutlookRadNet raised its 2026 sales outlook for the Imaging Center segment but maintained the same for Digital Health.

Imaging Center revenue guidance was raised to $2.37-$2.42 billion from the prior $2.355-$2.405 billion projection. Adjusted EBITDA guidance increased to $345-$358 million from $340-$353 million, while free cash flow guidance moved up to $115-$125 million from $112-$122 million.

For the Digital Health segment, RadNet reiterated its 2026 guidance. Total net revenues, including intersegment revenues, are expected to be $135-$145 million, while adjusted EBITDA is projected to be in the band of $10-$12 million.

RadNet's AI Rollout Targets ProductivityRadNet received FDA clearance for its DeepHealth breast ultrasound solution, which automates lesion detection, measurements, characterization and reporting. In validation studies, the product improved breast cancer detection sensitivity by 8% and reduced radiologist interpretation time by 37%.

The company plans to deploy the solution across its network by year-end, covering nearly 1 million annual breast ultrasound studies. Management also expects close to 15% of RadNet volumes to run through AI-powered automated draft-reporting solutions by year-end, rising to more than 50% by the end of the second quarter of 2027.

RDNT’s Zacks Rank & Key PicksRadNet currently has a Zacks Rank #4 (Sell).

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , The Cooper Companies (COO - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

West Pharmaceutical has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.40%.

The Cooper Companies reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10.00%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

The Cooper Companies has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.80%.

Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.

Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.27%.

RadNet, Inc. (RDNT) Q2 2026 Earnings Call Transcript

For the quarter ended June 2026, RadNet (RDNT - Free Report) reported revenue of $622.72 million, up 25% over the same period last year. EPS came in at $0.29, compared to $0.31 in the year-ago quarter.

The reported revenue represents a surprise of +1.77% over the Zacks Consensus Estimate of $611.91 million. With the consensus EPS estimate being $0.18, the EPS surprise was +61.11%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how RadNet performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenue- Digital Health: $32.4 million versus $32.86 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +56.5% change.Revenue- Revenue under capitation arrangements: $30.13 million versus the two-analyst average estimate of $31.59 million. The reported number represents a year-over-year change of -0.1%.Revenue- Service fee: $592.59 million versus the two-analyst average estimate of $584.29 million. The reported number represents a year-over-year change of +26.6%.View all Key Company Metrics for RadNet here>>>

Shares of RadNet have returned +10.3% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Total Company Revenue increased 25.0% to a quarterly record of $622.7 million in the second quarter of 2026 from $498.2 million in the second quarter of 2025Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 56.5% to a quarterly record of $32.4 million in the second quarter of 2026 from $20.7 million in the second quarter of 2025; Annual Recurring Revenue(4) (ARR) increased from $53.5 million at June 30, 2025 to $105.5 million at June 30, 2026 and sequentially increased from $96.9 million at March 31, 2026Total Company Adjusted EBITDA(1) was a quarterly record of $99.7 million in the second quarter of 2026 as compared with $81.2 million in the second quarter of 2025, an increase of 22.7%; Digital Health reportable segment Adjusted EBITDA(1) was $2.5 million in the second quarter of 2026 compared with $3.4 million in the second quarter of 2025, the result of continued infrastructure investments to fuel growthImaging Center Segment Adjusted EBITDA(1) margin increased by 17 basis points to 16.1% in the second quarter of 2026 from 16.0% in the second quarter of 2025Adjusting for unusual or one-time items, Adjusted Earnings(3) was $23.2 million and Adjusted Earnings Per Share(3) was $0.29 for the second quarter of 2026 as compared with Adjusted Earnings(3) of $25.7 million and Adjusted Earnings Per Share(3) of $0.34 for the second quarter of 2025  As a percentage of total procedural volumes, advanced imaging increased by 238 basis points to 29.9% in the second quarter of 2026 from 27.5% in the second quarter of 2025In the second quarter of 2026, aggregate advanced imaging (MRI, CT and PET/CT) procedural volumes increased 21.2% and same-center advanced imaging procedural volumes increased 9.6% as compared with the second quarter of 2025As of June 30, 2026, balance sheet cash was $726.3 million and Net Debt to Adjusted EBITDA(1) Ratio(5) was 1.8xRadNet revises full-year 2026 Imaging Center guidance levels with increases to Revenue, Adjusted EBITDA(1) and Free Cash Flow(2) and reaffirms all Digital Health guidance ranges
LOS ANGELES, Aug. 09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet” or the “Company”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 442 owned and operated outpatient imaging centers, today reported financial results for its second quarter of 2026.

Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “The Imaging Center and Digital Health reportable operating segments continue to demonstrate strong growth and achieve record quarterly results. In the second quarter of 2026, Total Company Revenue grew 25.0% and Digital Health segment Revenue increased 56.5% from last year’s same quarter. Growth was driven by strong increases in aggregate and same center procedural volumes, the contribution from recent acquisitions, a continuing shift in procedural volumes towards advanced imaging and incremental Digital Health sales and licenses of Enterprise Imaging and AI solutions.”

Dr. Berger continued, “Within the Imaging Center operating segment, we continue to have success in driving more advanced imaging procedures and increasing advanced imaging capacity through a variety of operating and Digital Health technology initiatives. Aggregate advanced imaging procedural volumes increased 21.2% and same-center advanced imaging procedural volumes increased 9.6% as compared with the second quarter of 2025. The disproportionally higher growth in MR, CT and PET/CT relative to routine imaging contributed to a 238 basis point shift in RadNet’s advanced imaging procedural volume mix as compared with the same quarter last year, increasing from 27.5% in last year’s second quarter to 29.9% in the second quarter of 2026. This favorable business mix shift contributed to a 16.1% Adjusted EBITDA(1) margin for the Imaging Center segment during this year’s second quarter, a 17 basis point improvement as compared with last year’s second quarter.”

“The Digital Health division continues to make significant progress. At June 30, 2026, ARR was $105.5 million, an increase of 97.2% from June 30, 2025 and an increase of 8.9% sequentially from March 31, 2026. ARR generated by external (non- RadNet) customers now comprises approximately 63% of Digital Health Revenue. During the second quarter, we signed new business with Total Contract Value of approximately $21 million, bringing our six-month new business Total Contract Value to approximately $37 million. The majority of our new business is with hospitals and health systems and spans the full breadth of DeepHealth AI and Enterprise Imaging solutions. On the regulatory front, at the end of July, DeepHealth’s breast ultrasound AI solution was cleared by the FDA. We expect to implement this solution across RadNet’s breast imaging centers by year-end and anticipate both Revenue and cost savings contributions in the second half of this year from the roll-out,” added Dr. Berger.

Dr. Berger continued, “Our joint venture business continues to grow. As of the end of the second quarter, 157 of our 442 locations (or approximately 36%) were held within health system partnerships. During the second quarter, we announced a multi-site joint venture in Boise, Idaho with Trinity Health’s Saint Alphonsus Health System to initially include the operations of five multimodality outpatient imaging centers. As part of the relationship, our contracted radiology group, Gem State Radiology, and the Saint Alphonsus hospitals in Boise will be adopting a variety of DeepHealth solutions including Diagnostic Suite, Reporting Pro, AI Studio and various clinical AI.”

“Given the positive trends within the industry and RadNet’s strong financial performance of the second quarter, we are revising upwards 2026 Imaging Center guidance levels for Revenue, Adjusted EBITDA(1) and Free Cash Flow(2) in anticipation of financial results that we believe will exceed both our original expectations and the amendments we made to the guidance ranges upon releasing first quarter 2026 results in May,” concluded Dr. Berger.  

Second Quarter Financial Results

For the second quarter of 2026, RadNet reported Total Company Revenue of $622.7 million and Adjusted EBITDA(1) of $99.7 million. Revenue increased $124.5 million (or 25.0%) and Adjusted EBITDA(1) increased $18.4 million (or 22.7%) as compared with the second quarter of 2025.  

For the second quarter of 2026, RadNet reported Digital Health Revenue (inclusive of intersegment revenue) of $32.4 million and Adjusted EBITDA(1) of $2.5 million. Revenue increased $11.7 million (or 56.5%) and Adjusted EBITDA(1) decreased $0.9 million (or 27.2%) as compared with the second quarter of 2025. The decrease in Digital Health Adjusted EBITDA(1) resulted predominantly from investments in headcount to fuel growth in sales, marketing, customer service and implementation teams. At June 30, 2026, Annual Recurring Revenue(4) (ARR) for Digital Health was $105.5 million, as compared with $53.5 million as of June 30, 2025.

Unadjusted for unusual or one-time items impacting the second quarter of 2026, Total Company Net Income for the second quarter of 2026 was $7.5 million as compared with a Total Company Net Income of $14.5 million for the second quarter of 2025. Net Income Per Share for the second quarter of 2026 was $0.10, compared with a Net Income per share of $0.19 in the second quarter of 2025, based upon a weighted average number of diluted shares outstanding of 78.7 million shares in 2026 and 75.5 million shares in 2025.

There were a number of unusual or one-time items impacting the second quarter including: $0.5 million expense related to leases for de novo facilities under construction that have yet to open their operations; $5.1 million of non-capitalized research and development expenses with respect to DeepHealth solutions; $6.8 million of Intangibles amortization within the Digital Health division primarily related recent acquisitions; $1.3 million of lease abandonment charges; $6.6 million of acquisition transaction costs; $3.2 million gain on the change in contingent consideration related to recent acquisitions; and $3.4 million loss from debt restructuring and extinguishment related to our recent debt repricing transaction. Adjusting for the above items, Total Company Adjusted Earnings(3) was $23.2 million and diluted Adjusted Earnings Per Share(3) was $0.29 during the second quarter of 2026. This compares with Total Company Adjusted Earnings(3) of $25.7 million and diluted Adjusted Earnings Per Share(3) of $0.34 during the second quarter of 2025.

For the second quarter of 2026, as compared with the prior year’s second quarter, MRI volume increased 21.0%, CT volume increased 20.9%, PET/CT volume increased 31.0% and routine imaging (inclusive of nuclear medicine, ultrasound, mammography, x-ray and other exams) increased 7.9% over the prior year’s second quarter. On a same-center basis, including only those centers which were part of RadNet for both the second quarters of 2026 and 2025, MRI volume increased 10.2%, CT volume increased 8.6%, PET/CT volume increased 8.8% and routine imaging increased 1.7% over the prior year’s second quarter.

Six Month Financial Results

For the first six months of 2026, RadNet reported Total Company Revenue of $1,198 million and Adjusted EBITDA(1) of $162.9 million. Revenue increased $228.7 million (or 23.6%) and Adjusted EBITDA(1) increased $35.3 million (or 27.6%) as compared with the first six months of 2025.   

For the first six months of 2026, RadNet reported Digital Health Revenue (inclusive of intersegment revenue) of $61.5 million and Adjusted EBITDA(1) of $3.8 million. Revenue increased $21.6 million (or 54.1%) and Adjusted EBITDA(1) decreased $3.3 million (or 46.9%) as compared with the first six months of 2025.

Unadjusted for one-time or unusual items, Total Company Net Loss for the first six months of 2026 was $25.9 million as compared with a Total Company Net Loss of $23.5 million for the first six months of 2025. Net Loss Per Share for the six-month period of 2026 was $(0.33), compared with a Net Loss per share of $(0.32) in the six-month period of 2025, based upon a weighted average number of diluted shares outstanding of 77.4 million shares in 2026 and 74.1 million shares in 2025.

2026 Guidance Update

RadNet updates guidance levels as follows:

Imaging Center Segment Original Guidance
RangeRevised Guidance
Range After Q1 ResultsRevised Guidance
Range After Q2 ResultsTotal Net Revenue$2,325 - $2,375 million$2,355 - $2,405 million$2,370 - $2,420 millionAdjusted EBITDA(1)$335 - $348 million$340 - $353 million$345 - $358 millionCapital Expenditures(a)$165 - $175 million$165 - $175 million$165 - $175 millionCash Interest Expense(b)$45 - $50 million$45 - $50 million$48 - $53 millionFree Cash Flow(2)$105 - $115 million$112 - $122 million$115 - $125 million (a)   Net of proceeds from the sale of equipment and New Jersey Imaging Network capital expenditures.
(b)   Net of payments from counterparties on interest rate swaps and interest income from our cash balance recorded in Other Income.

Digital Health Segment Original
Guidance Range
Revised
Guidance Range After
Q1 Results
Revised
Guidance Range After
Q2 Results    Total Net Revenue (inclusive of intersegment revenue)$135 - $145 million$135 - $145 million$135 - $145 million    Adjusted EBITDA(1)Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI$10 - $12 million$10 - $12 million$10 - $12 million    Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI$17 - $19 million$17 - $19 million$17 - $19 million    Capital Expenditures$9 - $12 million$9 - $12 million$9 - $12 million    Free Cash Flow(2)Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI$(1) - $3 million$(1) - $3 million$(1) - $3 million    Free Cash Flow(2)After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI$(17) - $(19) million$(17) - $(19) million$(17) - $(19) million
Conference Call for Tomorrow

Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its second quarter 2026 results on Monday, August 10th, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Conference Call Details:

Date: Monday, August 10, 2026
Time: 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time)
Dial In-Number: 844-744-1280
International Dial-In Number: 412-564-6465

It is recommended that participants dial in approximately 5 minutes prior to the start of the call. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1770869&tp_key=f4d7c2481f or http://www.radnet.com under the “News” menu section of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10210872.

About RadNet, Inc.

RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit http://www.radnet.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, guidance and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

the impact of a pandemic, significant deterioration in the broader economy, severe acts of nature or other exogenous factors on our business, suppliers, payors, customers, referral sources, partners, patients and employees;the availability and terms of capital to fund our business;our ability to service our indebtedness, make principal and interest payments as those payments become due and remain in compliance with applicable debt covenants, in addition to our ability to refinance such indebtedness on acceptable terms;changes in general economic conditions nationally and regionally in the markets in which we operate;the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities;our ability to maintain our current credit rating and the impact on our funding costs and competitive position if we do not do so;our ability to acquire, develop, implement and monetize artificial intelligence algorithms and applications;volatility in interest and exchange rates, or credit markets;the adequacy of our cash flow and earnings to fund our current and future operations;changes in service mix, revenue mix and procedure volumes;delays in receiving payments for services provided;increased bankruptcies among our partner physicians or joint venture partners;the impact of the political environment and related developments on the current healthcare marketplace and on our business, including with respect to the future of the Affordable Care Act;the extent to which the ongoing implementation of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof by federal and state regulators or related litigation result in a reduction in coverage or reimbursement rates for our services, or other material impacts to our business;closures or slowdowns and changes in labor costs and labor difficulties, including stoppages affecting either our operations or our suppliers' abilities to deliver supplies needed in our facilities;the occurrence of hostilities, political instability or catastrophic events;the emergence or reemergence of and effects related to future pandemics, epidemics and infectious diseases; andnoncompliance by us with any privacy or security laws or any cybersecurity incident or other security breach by us or a third party involving the misappropriation, loss or other unauthorized use or disclosure of confidential information.With respect to mergers and acquisitions: (1) the termination of or occurrence of any event, change or other circumstances that could give rise to the termination of the merger or acquisition agreement or the inability to complete the proposed transaction on the anticipated terms and timetable, (2) the inability to complete the proposed transaction due to any applicable regulatory approval that may be required for the proposed transaction that is delayed, that is not obtained or that is obtained subject to conditions that are not anticipated, (3) the ability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, the ability to maintain relationships with its customers, patients, payers, physicians, and providers and retain its management and key employees, (4) the ability of RadNet following the proposed transaction to achieve the synergies contemplated by the proposed transaction or such synergies taking longer to realize than expected, (5) costs related to the proposed transaction, (6) the ability of RadNet following the proposed transaction to execute successfully its strategic plans, (7) the ability of RadNet following the proposed transaction to promptly and effectively integrate the target into its business, (8) the risk of litigation related to the proposed transaction, (9) the diversion of management's time and attention from ordinary course business operations to completion of the proposed transaction and integration matters, (10) the risk of legislative, regulatory, economic, competitive, and technological changes, (11) risks relating to the value of RadNet's securities to be issued in the proposed merger, and (12) the effect of the announcement, pendency or completion of the proposed transactions on the market price of RadNet’s common stock.
The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet's filings with the United States Securities and Exchange Commisssion (the “SEC”), including the risk factors discussed in RadNet's most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

Any forward-looking statement contained in this release is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable law.

Regulation G: GAAP and Non-GAAP Financial Information

This release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.

CONTACTS:

RadNet, Inc.
Mark Stolper, 310-445-2800
Executive Vice President and Chief Financial Officer     

RADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)     June 30, 2026 December 31, 2025 (unaudited)  ASSETS   CURRENT ASSETS   Cash and Cash equivalents$726,272  $767,215 Accounts receivable 241,845   200,317 Due from affiliates 6,863   12,592 Prepaid expenses and other current assets 60,776   52,003 Total current assets 1,035,756   1,032,127 PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS   Property and equipment, net 879,904   807,702 Operating lease right-of-use assets 759,225   690,250 Total property, plant, equipment and right-of-use assets 1,639,129   1,497,952 OTHER ASSETS   Goodwill 1,122,468   907,663 Other intangible assets 245,348   148,508 Deferred financing costs 1,393   1,684 Investment in joint ventures 135,019   130,340 Deposits and other 47,238   40,289 Total Assets$4,226,351  $3,758,563     LIABILITIES AND EQUITY   CURRENT LIABILITIES   Accounts payable, accrued expenses and other$489,818  $422,029 Due to affiliates 91,298   70,104 Deferred revenue 16,480   7,272 Current operating lease liability 69,557   61,934 Current portion of notes payable 30,669   25,424 Total current liabilities 697,822   586,763 LONG-TERM LIABILITIES   Long-term finance lease liability 4,288   - Long-term operating lease liability 776,329   707,001 Notes payable, net of current portion 1,301,862   1,064,495 Deferred tax liability, net 39,005   21,903 Other non-current liabilities 12,994   22,515 Total liabilities 2,832,300   2,402,677 EQUITY   RadNet, Inc. stockholders' equity:   Common stock - $0.0001 value, 200,000,000 shares authorized; 78,646,805 and 77,399,615 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively 8   8 Additional paid-in-capital 1,222,961   1,180,434 Accumulated other comprehensive loss (5,504)  4,885 Accumulated deficit (121,373)  (95,437)Total RadNet, Inc.'s Stockholders' equity: 1,096,092   1,089,890 Noncontrolling interests 297,959   265,996 Total Equity 1,394,051   1,355,886 Total liabilities and equity$4,226,351  $3,758,563  RADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENT OF OPERATIONS(IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE DATA)(unaudited) Three Months Ended June 30, Six Months Ended June 30,  2026   2025   2026   2025         REVENUE       Service fee revenue$592,589  $468,063  $1,137,807  $907,412 Revenue under capitation arrangements 30,131   30,167   60,544   62,217 Total service revenue 622,720   498,230   1,198,351   969,629 OPERATING EXPENSES       Cost of operations, excluding depreciation and amortization 534,640   429,085   1,085,152   882,565 Lease abandonment charges 1,306   123   1,306   5,511 Depreciation and amortization 45,529   35,993   90,496   71,476 Loss (gain) on sale and disposal of equipment and other 1,117   1,724   3,708   2,126 Severance costs 660   426   2,124   1,173 Total operating expenses 583,252   467,351   1,182,786   962,851 INCOME (LOSS) FROM OPERATIONS 39,468   30,879   15,565   6,778 OTHER INCOME AND EXPENSES       Interest expense 18,153   17,189   35,810   34,428 Equity in earnings of joint ventures (4,710)  (4,356)  (8,535)  (6,955)Non-cash change in fair value of interest rate hedge -   1,956   -   4,062 Debt restructuring and extinguishment expenses 3,368   -   3,368   - Other (income) expenses (3,960)  (7,764)  (8,867)  (15,476)Total other (income) expenses 12,851   7,025   21,776   16,059 INCOME (LOSS) BEFORE INCOME TAXES 26,617   23,854   (6,211)  (9,281)Provision for income taxes (6,363)  (820)  1,733   2,578 NET INCOME (LOSS) 20,254   23,034   (4,478)  (6,703)Net income (loss) attributable to noncontrolling interests 12,724   8,580   21,458   16,769 NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$7,530  $14,454  $(25,936) $(23,472)        BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$0.10  $0.19  $(0.33) $(0.32)        DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$0.10  $0.19  $(0.33) $(0.32)WEIGHTED AVERAGE SHARES OUTSTANDING       Basic 77,788,452   74,352,498   77,425,061   74,070,438 Diluted 78,731,021   75,531,743   77,425,061   74,070,438          RADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS(IN THOUSANDS)(unaudited) Six Months Ended June 30,  2026   2025 CASH FLOWS FROM OPERATING ACTIVITIES   Net loss$(4,478) $(6,703)Adjustments to reconcile net loss to net cash provided by operating activities:   Depreciation and amortization 90,496   71,476 Noncash operating lease expense 32,658   29,356 Equity in earnings of joint ventures, net of dividends (4,679)  (1,267)Amortization of deferred financing costs and loan discount 1,550   1,471 Loss on sale and disposal of equipment 3,708   2,126 Loss on extinguishment of debt 407   - Lease abandonment charges 1,306   5,511 Amortization of cash flow hedge -   2,712 Non-cash change in fair value of interest rate swap -   4,062 Stock-based compensation 41,915   37,235 Change in fair value of contingent consideration (393)  - Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:   Accounts receivable (23,413)  (14,159)Other current assets (1,131)  22,381 Other assets (7,443)  (2,544)Deferred taxes (3,784)  (3,511)Operating leases (29,238)  (34,726)Deferred revenue 1,016   145 Accounts payable, accrued expenses and other 74,574   48,264 Net cash provided by operating activities 173,071   161,829 CASH FLOWS FROM INVESTING ACTIVITIES   Purchase of imaging facilities and other acquisitions, net of cash acquired (315,707)  (31,985)Purchase of property and equipment and other (126,215)  (101,776)Proceeds from sale of equipment 744   40 Equity contributions in existing and purchase of interest in joint ventures -   (20,480)Collection of notes receivable 6,651   - Net cash used in investing activities (434,527)  (154,201)CASH FLOWS FROM FINANCING ACTIVITIES   Principal payments on notes and leases payable (11,767)  (3,461)Payments on Term Loan Debt (11,140)  (10,252)Proceeds from issuance of new debt, net of issuing costs 248,937   99,001 Purchase of noncontrolling interests by third party -   2,389 Distributions paid to noncontrolling interests (3,927)  (3,313)Proceeds from issuance of common stock upon exercise of options 612   554 Net cash provided by financing activities 222,715   84,918 EFFECT OF EXCHANGE RATE CHANGES ON CASH (2,202)  586 NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (40,943)  93,132 CASH AND CASH EQUIVALENTS, beginning of period 767,215   740,020 CASH AND CASH EQUIVALENTS, end of period 726,272   833,152     SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION   Cash paid during the period for interest$35,632  $35,018 Cash paid during the period for income taxes$2,143  $2,428      RADNET, INC. AND SUBSIDIARIESRECONCILIATION OF GAAP NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS TO ADJUSTED EBITDA(IN THOUSANDS) Three Months Ended June 30, Six Months Ended June 30,  2026   2025   2026   2025         Net income (loss) attributable to Radnet, Inc. common stockholders$7,530  $14,454  $(25,936) $(23,472)Income taxes 6,363   820   (1,733)  (2,578)Interest expense 18,153   17,189   35,810   34,428 Severance costs 660   426   2,124   1,173 Depreciation and amortization 45,529   35,993   90,496   71,476 Non-cash employee stock-based compensation 10,540   8,741   41,915   37,235 Loss (gain) on sale and disposal of equipment and other 1,117   1,724   3,708   2,126 Non-cash change in fair value of interest rate hedge -   1,956   -   4,062 Other expenses (income) (3,960)  (7,764)  (8,867)  (15,476)Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI 5,110   4,787   9,670   8,349 Lease abandonment charges 1,306   123   1,306   5,511 Loss (gain) on extinguishment of debt and related expenses 3,368   -   3,368   - Non-cash change to contingent consideration (3,157)  -   (393)  - Non-operational rent expenses 498   496   1,398   1,838 Acquisition transaction costs 6,599   2,301   10,053   2,973         Adjusted EBITDA - Radnet, Inc.$99,656  $81,246  $162,919  $127,645         NOTE       Adjusted EBITDA - Imaging Center Segment 97,178   77,843   159,138   120,531 Adjusted EBITDA - Digital Health Segment 2,478   3,403   3,781   7,114           PAYMENTS BY PAYOR CLASS        Second Quarter  2026
    Commercial Insurance57.2% Medicare24.2% Capitation4.8% Medicaid2.3% Workers Compensation/Personal Injury2.2% Other*9.2% Total100.0%    * Includes Management Fees, Digital Health Revenue and Heart Lung Health Revenue.    RADNET PAYMENTS BY MODALITY                       Second QuarterFull Year Full Year Full Year   2026
 2025
 2024
 2023
           MRI 38.5% 37.7% 37.1% 36.8% CT 16.3% 15.6% 15.9% 16.8% PET/CT 9.9% 8.8% 7.2% 6.4% X-ray 5.0% 5.5% 6.0% 6.5% Ultrasound 12.8% 13.5% 13.6% 12.9% Mammography 14.2% 15.6% 16.4% 16.0% Nuclear Medicine 0.9% 0.9% 1.0% 0.8% Other 2.5% 2.5% 2.7% 3.9%   100.0% 100.0% 100.0% 100.0%             PROCEDURES BY MODALITY*         Second QuarterSecond Quarter   2026 2025        MRI593,143 490,299  CT352,734 291,820  PET/CT29,027 22,155  Nuclear Medicine10,460 9,377  Ultrasound776,541 701,917  Mammography537,732 508,000  X-ray and Other962,376 900,095        Total
3,262,013 2,923,663        * Volumes include wholly owned and joint venture centers.        RADNET, INC. AND SUBSIDIARIESSCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE(3)(IN THOUSANDS EXCEPT SHARE DATA)(unaudited)     Three Months Ended June 30,  2026  2025 (iv)    NET INCOME ATTRIBUTABLE TO RADNET, INC.   COMMON STOCKHOLDERS$7,530  $14,454     Add/Subtract non-cash change in fair value of interest rate swaps (i) -   1,956 Non-operational rent expenses (iii) 498   496 Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI 5,110   4,787 Intangibles Amortization Expense - Digital Health Operating Segment (v) 6,838   2,032 Lease abandonment charge 1,306   123 Acquisition transaction costs 6,599   2,301 Change to contingent consideration (3,157)  - Debt restructing and extinguishment expenses (iv) 3,368   - Total adjustments - loss (gain) 20,562   11,695 Subtract tax impact of Adjustments (ii) (4,916)  (402)Tax effected impact of adjustments 15,646   11,293     TOTAL ADJUSTMENT TO NET INCOME ATTRIBUTABLE   TO RADNET, INC. COMMON SHAREHOLDERS 15,646   11,293     ADJUSTED NET INCOME ATTRIBUTABLE TO RADNET, INC. 23,176   25,747 COMMON STOCKHOLDERS       WEIGHTED AVERAGE SHARES OUTSTANDING   Diluted 78,731,021   75,531,743     ADJUSTED DILUTED NET INCOME PER SHARE   ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$0.29  $0.34     (i) Impact from the change in fair value of the swaps during the quarter. Excludes the recurring amortization of the accumulation of the changes in fair value out of Other Comprehensive Income that existed prior to the hedges becoming ineffective.
(ii) Tax effected using 23.91% and 3.44% blended federal and state effective tax rate for the second quarter of 2026 and 2025, respectively.(iii) Represents rent expense associated with de novo sites under construction prior to them becoming operational.
(iv) Extraordinary expense related to the Company's successful June 2026 debt repricing and add-on transaction.
(v) Intangible amortization expense related to the Digital Health operating segment.
(vi) Adjusted from what was reported during last year's second quarter for an additional addback of $2,032,000 related to DeepHealth amortization of intangibles primarily resulting from recent acquisitions.     Footnotes

(1) The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taken place during the period.

Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

(2) As noted above, the Company defines Free Cash Flow as Adjusted EBITDA less total Capital Expenditures (whether completed with cash or financed) and Cash Interest Expense. Free Cash Flow is a non-GAAP financial measure. The Company uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other companies.

Free Cash Flow should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

(3) The Company defines Adjusted Earnings (Loss) Per Share as net income or loss attributable to RadNet, Inc. common stockholders and excludes losses or gains on the disposal of equipment, loss on debt extinguishments, bargain purchase gains, severance costs, loss on impairment, loss or gain on swap valuation, gain on extinguishment of debt, unusual or non-recurring entries that impact the Company’s tax provision and any other non-recurring or unusual transactions recorded during the period.

Adjusted Earnings (Loss) Per Share is reconciled to its nearest comparable GAAP financial measure. Adjusted Earnings (Loss) Per Share is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance. Adjusted Earnings Per Share should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted Earnings Per Share should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted Earnings Per Share is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

(4) We use Annual Recurring Revenue (“ARR”) as a key operating metric to evaluate the scale, growth and health of the recurring component of our Digital Health business. We define ARR as a key subscription-economy metric representing the predictable, normalized annualized value of contracted recurring revenue generated from active customer contracts. ARR includes subscription fees, recurring support fees and contracted usage charges, and excludes one-time or non-recurring fees, such as implementation fees, hardware sales, professional services, consulting and one-time training.   ARR is determined based on the contractual terms of active customer arrangements and is not calculated by reference to revenue recognized under GAAP, deferred revenue or another GAAP financial measure. Accordingly, ARR is an operating metric and not a non-GAAP financial measure. ARR should be viewed independently of revenue and deferred revenue and is not intended to be combined with, or to replace, either measure. ARR is not a forecast of future revenue, which may be affected by contract start and end dates, cancellations, renewal rates, customer usage and other factors. ARR does not have a standardized definition and may not be comparable to similarly titled measures presented by other companies.

(5) Net Debt to Adjusted EBITDA(1) Ratio is calculated by taking our Total Debt at par value less our cash balance divided by our Adjusted EBITDA(1). This amount excludes our joint venture partner’s proportionate share (51%) of the Net Debt of New Jersey Imaging Network.

SOMERVILLE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced FDA 510(k) clearance for DeepHealth Breast Ultrasound,1 an AI-powered solution that brings greater standardization, clinical accuracy and efficiency to breast ultrasound imaging. DeepHealth Breast Ultrasound automates lesion detection, characterization and reporting, streamlining sonographer and radiologist workflows in one intelligent experience. Together with its AI-powered mammography solutions, the expanded DeepHealth breast platform is the most comprehensive in the industry.

In addition to a multi-reader multi-case study involving 16 U.S. board-certified radiologists at select imaging centers and hospitals,2 RadNet has validated the effectiveness of DeepHealth Breast Ultrasound in live clinical settings under regulated research protocols. Now with FDA clearance, DeepHealth Breast Ultrasound is commercially available for sale to customers in the United States who can pursue reimbursement under an existing Category III CPT code for quantitative ultrasound tissue characterization.3 By the end of this year, the solution will be implemented across RadNet’s network of centers, with an estimated more than 700,000 breast ultrasound studies annually that may be eligible for reimbursement.

“Breast ultrasound is an essential component of the breast care pathway, with approximately 40% of women undergoing the exam at some point in their lives.4 It is a highly complex, operator-dependent examination, which can lead to significant variability in image acquisition, interpretation and reporting,” said Dr. Jason McKellop, Medical Director of Women's Imaging for RadNet California. “With DeepHealth's breast ultrasound solution, we can achieve greater standardization of workflows, improving consistency while saving time for patients, sonographers and radiologists. By streamlining the examination process, we can help reduce exam times, enhance efficiency and ultimately improve patient outcomes.”

DeepHealth Breast Ultrasound is designed to support more efficient and standardized ultrasound workflows through:

Automated lesion detection – Assists the interpreting physician to localize the presence or absence of suspicious soft-tissue lesions in standard ultrasound breast images, with demonstrated greater than 98% accuracy in localizing breast lesions and improved sensitivity for breast cancer detection by 8%2Automated lesion characterization – Analyzes images acquired by the sonographer to assist the interpreting physician in generating and characterizing the lesion shape, orientation, margin, echo pattern and posterior features, in line with ACR BI-RADS, reducing radiologist interpretation time by 37%2Automated reporting – Generates a comprehensive radiology report of the key findings and impressions, helping radiologists move more efficiently from image review to final report while retaining control of the final assessmentExpedited sonographer workflow – Automatically extracts and organizes lesion measurements, characteristics and other relevant findings in a standardized format, reducing manual documentation for sonographers with the aim of reducing overall exam time “No single imaging pathway addresses every woman’s needs. With the addition of Breast Ultrasound, we are proud to support women across a broader range of screening and diagnostic pathways, including those with dense breasts and others who may require supplemental imaging. Bringing together AI-powered capabilities across mammography and ultrasound helps clinicians respond to different imaging needs and deliver more comprehensive, personalized breast care,” said Niccolò Stefani, M.D., Business and Product Leader, Clinical AI at DeepHealth.

DeepHealth’s breast imaging platform5 — a modular, interoperable AI-powered portfolio addressing real-world clinical needs across breast cancer screening and diagnostic pathways — includes applications for cancer detection in both mammography and ultrasound, density assessment, breast arterial calcification assessment, image-based breast cancer risk prediction6 and mammography quality analytics, with viewing and reporting tools for improved operational efficiency.

About DeepHealth
DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, musculoskeletal, neuro, prostate and thyroid health. At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow. Thousands of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. Learn more at deephealth.com. 

About RadNet, Inc. 
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 12,000 team members. Learn more at radnet.com. 

Forward Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding our technology’s ability to stage-shift disease through proactive, timely intervention and discussions regarding our product features. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet, nor any of its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the technology. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes, and other risks and uncertainties described in the “Risk Factors,” “Management’s Discussion and Analysis,” and other sections of our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

DeepHealth Media Contact
Andra Axente
Director of Communications
+31614440971
[email protected]

RadNet Media Contacts 
Jane Mazur 
Senior Vice President, Corporate Communications 
+1 585-355-5978 
[email protected]

Mark Stolper
Executive Vice President and Chief Financial Officer
+1 310-445-2800

References

Deephealth Breast Ultrasound is the commercial name for the See-Mode Augmented Reporting Tool, Breast (SMART-B) device, cleared by the FDA under 510(k) K260303. The clearance is held by See-Mode Technologies Pty Ltd, a DeepHealth company, which manufactures the device; it is distributed in the United States by DeepHealth, Inc.Data on file. Based on data from MRMC study submitted to FDA for 510(k) clearance K260303.Reimbursement depends on payer policy.Based on change of regulations and gold-standard approach in breast cancer screening. U.S. Food and Drug Administration. Mammography Quality Standards Act and Regulation Amendments: Small Entity Compliance Guide—Guidance for Industry and Food and Drug Administration Staff. Issued August 26, 2024, https://www.fda.gov/media/181152/download.
U.S. Food and Drug Administration. Understanding Breast Density. FDA Office of Women’s Health. https://www.fda.gov/consumers/womens-health-topics/understanding-breast-densityDeepHealth breast solutions comprise multiple applications, including Mammo Dx, Breast Density, Safeguard Review, Risk Assessment, BAC Assessment, Mammography Insight, Breast Ultrasound and workflow tools including DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Mammography Insights is manufactured by Aquila, Inc. and distributed by DeepHealth, Inc. Not cleared for use in the U.S. Capability available in Europe. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b8473709-04f0-4b5c-b856-bab20d7d6c80

DeepHealth Breast Ultrasound DeepHealth Breast Ultrasound

Posted by Defense World Staff on Jul 19th, 2026

Bessemer Group Inc. grew its holdings in shares of RadNet, Inc. (NASDAQ:RDNT – Free Report) by 11.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 550,172 shares of the medical research company’s stock after purchasing an additional 56,173 shares during the quarter. Bessemer Group Inc. owned about 0.70% of RadNet worth $30,749,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of RDNT. Geneos Wealth Management Inc. acquired a new position in RadNet during the fourth quarter worth $25,000. Allworth Financial LP lifted its position in shares of RadNet by 346.6% in the third quarter. Allworth Financial LP now owns 393 shares of the medical research company’s stock worth $30,000 after buying an additional 305 shares during the last quarter. Danske Bank A S bought a new position in shares of RadNet in the third quarter valued at approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in shares of RadNet in the fourth quarter worth $36,000. Finally, Harbour Investments Inc. acquired a new stake in shares of RadNet in the fourth quarter worth $42,000. Institutional investors and hedge funds own 77.90% of the company’s stock.

Analyst Ratings Changes A number of research firms recently issued reports on RDNT. Barclays lowered their target price on shares of RadNet from $70.00 to $65.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 20th. Weiss Ratings cut shares of RadNet from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, May 12th. Finally, Zacks Research cut shares of RadNet from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $87.43.

View Our Latest Research Report on RDNT

Insider Activity In related news, CEO Cornelis Wesdorp sold 4,750 shares of RadNet stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $58.11, for a total transaction of $276,022.50. Following the sale, the chief executive officer directly owned 69,075 shares of the company’s stock, valued at $4,013,948.25. This trade represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David L. Swartz sold 2,699 shares of the business’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $53.89, for a total value of $145,449.11. Following the transaction, the director owned 177,013 shares in the company, valued at $9,539,230.57. This represents a 1.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 5.60% of the stock is currently owned by company insiders.

RadNet Trading Down 1.3% Shares of RadNet stock opened at $62.19 on Friday. RadNet, Inc. has a 1 year low of $50.76 and a 1 year high of $85.84. The company’s fifty day simple moving average is $57.99 and its 200-day simple moving average is $62.76. The company has a market cap of $4.89 billion, a price-to-earnings ratio of -345.48 and a beta of 1.37. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.79.

RadNet (NASDAQ:RDNT – Get Free Report) last released its earnings results on Monday, May 11th. The medical research company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.14). RadNet had a negative net margin of 0.66% and a positive return on equity of 2.77%. The company had revenue of $575.63 million for the quarter, compared to analyst estimates of $557.93 million. During the same quarter in the previous year, the company earned ($0.50) earnings per share. RadNet’s revenue for the quarter was up 22.1% compared to the same quarter last year. As a group, sell-side analysts expect that RadNet, Inc. will post 0.54 EPS for the current year.

RadNet Profile (Free Report)

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.

Featured Articles Five stocks we like better than RadNet Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors Want to see what other hedge funds are holding RDNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RadNet, Inc. (NASDAQ:RDNT – Free Report).

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEGeneos Wealth Management Inc. Sells 12,023 Shares of Bank of America Corporation $BAC

NEXT HEADLINE »Apple Inc. $AAPL Shares Sold by Fischer Financial Services Inc.

SOMERVILLE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), announces it has received FDA 510(k) clearances for two new Breast Suite1 functionalities:

Breast Arterial Calcification (BAC) Assessment, a tool applied to standard screening mammograms that automatically identifies breast arterial calcifications, a potential early indicator of cardiovascular disease;2Prior exam integration into ProFound Pro, which enables automatic processing of prior and current studies to track prior lesions and distinguish new lesions, with the goal of improving cancer detection rates and reducing recalls. ProFound Pro with prior exam integration will be brought to market as Mammo Dx.3 The two additions reinforce Breast Suite as the industry’s most comprehensive end-to-end breast imaging AI suite—a modular, interoperable portfolio of applications addressing real-world clinical needs across breast cancer screening and diagnostic pathways. Both newly FDA cleared functionalities are now commercially available in the United States.

“Our strategy has always centered around using AI to find disease early. BAC Assessment and Mammo Dx are proof points of that strategy: one adds a cardiovascular evaluation to a routine breast cancer screening mammogram and the other incorporates changes from past mammogram exams into current mammograms to improve cancer detection. Together, they transform Breast Suite into a fully integrated suite of solutions that give radiologists a more complete patient overview and added clinical confidence in two of the top causes of death in U.S. women,” said Niccolo Stefani, MD, Business and Product Leader, Population Health & Clinical AI, DeepHealth.

BAC Assessment analyzes standard 2D (FFDM) and 3D (DBT) mammograms, automatically identifying and flagging breast arterial calcifications within the radiology workflow with no additional imaging required beyond the mammogram. BACs visible on mammograms have been linked to an elevated risk of future cardiovascular events, including heart attacks and strokes.2 In clinical performance testing, DeepHealth’s BAC Assessment demonstrated more than 90% sensitivity and more than 88% specificity in identifying arterial calcifications across both dense and non-dense breast tissue.4 BAC Assessment is now commercially available and will be deployed across RadNet imaging centers in the U.S., providing additional real-world validation of its capability.

With the addition of prior exams, Mammo Dx enables the comparison of breast tissue over time amongst prior and current exams and helps radiologists identify subtle changes with lesions that may be undetected on a single-exam read. Mammo Dx brings prior findings into the interpretation process, supporting more informed clinical decision-making with the ultimate goal of helping reduce false positives and better determining when additional diagnostic procedures may be warranted.

With these clearances, DeepHealth’s Breast Suite now includes BAC Assessment, Mammo Dx for cancer detection and diagnosis, automated breast density assessment and future cancer risk assessment,5 alongside workflow tools that elevate radiologist performance and enhance operational efficiency. Today, components of Breast Suite support diagnostic accuracy6 and standardization of care7 across more than 10 million mammograms performed annually across the world.

About DeepHealth
DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, musculoskeletal, neuro, prostate and thyroid health. At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow. Thousands of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. Learn more at deephealth.com. 

About RadNet, Inc. 
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members. Learn more at radnet.com. 

Forward Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding our technology’s ability to stage-shift disease through proactive, timely intervention and discussions regarding our product features. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet, nor any of its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the technology. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes, and other risks and uncertainties described in the “Risk Factors,” “Management’s Discussion and Analysis,” and other sections of our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

DeepHealth Media Contact
Andra Axente
Director of Communications
+31614440971
[email protected]

RadNet Media Contacts 
Jane Mazur 
Senior Vice President, Corporate Communications 
+1 585-355-5978 
[email protected]

Mark Stolper
Executive Vice President and Chief Financial Officer
+1 310-445-2800

References

Breast Suite comprises multiple applications, including Mammo Dx, Breast Density, Safeguard Review, Risk Assessment, BAC Assessment, DeepHealth Viewer, Mammography Insights and Breast Ultrasound. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Mammography Insights is manufactured by Aquila, Inc. and distributed by DeepHealth, Inc. Any claims made about Breast Suite may reference claims associated with its individual components.Nandurkar et al., “Breast Arterial Calcification as a Predictor for Future Cardiovascular Events and Mortality: A Systematic Review and Meta-analysis,” Journal of Breast Imaging, 2026.The FDA-cleared software previously known as ProFound Pro is now marketed as Mammo Dx including priors. Mammo Dx retains the FDA-cleared capabilities of ProFound Pro and serves as the foundation for ongoing innovation, with additional features and enhancements being introduced over time.FDA 510(k) clearance K254131. Clinical Performance Testing.Not cleared for use in the U.S. Capability available in Europe.Louis, L. et al. “Equitable Impact of an AI-Driven Breast Cancer Screening Workflow in Real World US-wide Deployment.” Nature Health, 2025.McCabe et al. “Multistage AI-Driven Workflow Improves General Radiologist Screening Mammography Performance to the Level of Fellowship-Trained Breast Imagers: Real-world Evidence in >500,000 Patients.” RSNA Chicago. 2025.

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced an expanded collaboration with DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), to further the innovation, commercialization, and adoption of advanced AI-powered mammography tools. The announcement coincides with the Society of Breast Imaging (SBI) Annual Symposium, where GE HealthCare will showcase its latest advancements in breast imaging and w.

On April 20, 2026, RadNet Inc RDNT shares fell 4.3% to a current price of $57.85. This decline comes after a mixed price performance, with the stock showing a 52-week range of $46.76 to $85.84. The year-to-date performance has been particularly poor, down 18.9%.

GF Value™ verdict: Current price vs GF Value of $64.47 indicates a 10.3% undervaluation.GF Score™ of 85/100 suggests a strong overall ranking.Notable signal: Insiders sold $1.9 million worth of shares in the last 3 months, with no buying activity. Is RDNT Overvalued or Undervalued? RadNet Inc's current price of $57.85 is below the GF Value™ estimate of $64.47, indicating that the stock is 10.3% undervalued. This margin of safety suggests that there may be an opportunity for potential appreciation in stock value. However, it's essential to recognize that while the GF Valuation label categorizes the stock as "Modestly Undervalued," the financial health and market conditions surrounding RadNet must also be considered. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

Investors should be cautious, as the recent decline in share price may reflect underlying challenges that could affect future performance. While the undervaluation indicates a potential upside, the stock's volatility and lack of insider buying activity may signal caution.

How Does RDNT's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 90.8x 117.6x RadNet's current forward P/E of 90.8x is significantly below its 5-year median P/E of 117.6x. This indicates that the stock is trading below its historical valuation levels. This P/E analysis aligns with the GF Value™ verdict of being undervalued, suggesting that RadNet may offer a more attractive entry point compared to its past valuations.

What Does RDNT's GF Score™ Tell Us? Metric Rating GF Score™ 85/100 Financial Strength 5/10 Profitability 6/10 Growth 8/10 Valuation 10/10 Momentum 7/10 The GF Score™ of 85/100 indicates that RadNet has a strong overall ranking, particularly in the Valuation category with a perfect score of 10/10. However, its Financial Strength rating of 5/10 suggests that there may be some areas of concern regarding its financial health. The Growth rank of 8/10 indicates solid potential for future growth, while the Profitability rank of 6/10 shows moderate profitability. Overall, RadNet appears to have strengths in valuation and growth, but weaker financial strength could be a risk factor.

What Are Insiders Doing with RDNT Stock? In the past three months, insiders at RadNet have sold $1.9 million worth of shares without any reported buying activity. This pattern of selling may suggest a lack of confidence among insiders regarding the company's immediate future performance. While insider selling does not necessarily indicate a negative outlook, it does warrant attention as it may reflect management's perception of the company's stock value at this time.

What This Means for Investors Based on the analysis of the GF Value™, RadNet Inc RDNT shares appear to be undervalued at the current price of $57.85, as indicated by the 10.3% margin to the GF Value™ estimate of $64.47. However, potential investors should consider the mixed signals from insider activity and financial strength ratings before making any decisions.

For the complete analysis, visit the RadNet Inc RDNT stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is RDNT's GF Score™?

RadNet has a GF Score™ of 85/100, indicating a strong overall ranking which suggests the company has potential for higher long-term returns.

Is RDNT overvalued or undervalued?

RadNet is currently undervalued, with a GF Value™ estimate indicating a 10.3% upside from its current price.

What is RDNT's P/E ratio?

The current forward P/E ratio for RadNet is 90.8x, which is below its 5-year median P/E of 117.6x, suggesting that the stock is trading at a lower valuation than it historically has.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

On April 29, 2026, RadNet Inc RDNT shares fell 3.5% to a current price of $55.89. Over the past week, the stock has declined by 3.4%, and it has decreased by 21.7% year-to-date. The shares have traded in a 52-week range from a low of $50.15 to a high of $85.84.

GF Value™ verdict: The current price is $55.89, indicating a 13.7% undervaluation compared to the GF Value™ of $64.75.GF Score™: RadNet has a GF Score™ of 84/100, suggesting it is a strong company with potential for long-term returns.Notable signal: Insider activity has been bearish, with insiders selling $1.9M worth of shares in the last three months and no buying activity reported. Is RDNT Overvalued or Undervalued? The current price of RadNet Inc is $55.89, which is below the GF Value™ estimate of $64.75. This represents a 13.7% margin of safety, indicating that the stock may be undervalued. The GF Valuation label classifies RadNet as modestly undervalued. While this suggests a potential buying opportunity, it is crucial to consider the underlying reasons for the stock's decline and the overall market conditions.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Investors should remain cautious, as the undervaluation does not guarantee immediate price appreciation; the stock could be facing headwinds that may impact its performance in the near term.

How Does RDNT's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 87.8x 118.7x RadNet's current forward P/E ratio of 87.8x is significantly lower than its 5-year median P/E ratio of 118.7x. This suggests that the stock is trading below its historical valuation, which is consistent with the GF Value™ verdict of being undervalued. The P/E analysis supports the idea that there may be an opportunity for potential price recovery, should the company navigate its challenges effectively.

What Does RDNT's GF Score™ Tell Us? Metric Rating GF Score™ 84/100 Financial Strength 5/10 Profitability 6/10 Growth 8/10 Valuation 10/10 Momentum 7/10 The GF Score™ of 84/100 indicates that RadNet is a strong company with a balanced profile. The highest rating comes from the Valuation category, where it scores 10/10, suggesting that the stock is attractively priced relative to its intrinsic value. However, financial strength ranks lower at 5/10, indicating potential concerns in that area. Overall, the scores suggest that while RadNet has promising growth potential, it may face challenges regarding its financial stability.

What Are Insiders Doing with RDNT Stock? Insider activity at RadNet has been notably bearish, with insiders selling $1.9 million worth of shares in the last three months and no reported buying. This pattern raises concerns about potential confidence issues among insiders regarding the company's future prospects. While insider selling can be a normal part of financial planning, the lack of buying may indicate hesitation about the company's short-term outlook.

What This Means for Investors Based on the analysis, RadNet Inc RDNT appears to be undervalued according to GF Value™, with a potential upside of 13.7% based on its current price compared to its intrinsic value estimate. However, investors should weigh this opportunity against the recent insider selling and the company's financial strength metrics.

For the complete analysis, visit the RadNet Inc RDNT stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is RDNT's GF Score™?

RadNet's GF Score™ is 84/100, indicating a strong company with potential for higher long-term returns based on various performance metrics.

Is RDNT overvalued or undervalued?

RadNet is considered undervalued, with a GF Value™ of $64.75 compared to its current price of $55.89, representing a 13.7% margin of safety.

What is RDNT's P/E ratio?

RadNet's current forward P/E ratio is 87.8x, which is significantly lower than its 5-year median P/E of 118.7x, indicating it is trading below its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

RadNet (RDNT - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The earnings report, which is expected to be released on May 11, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis operator of medical diagnostic imaging centers is expected to post quarterly loss of $0.14 per share in its upcoming report, which represents a year-over-year change of +60%.

Revenues are expected to be $567.54 million, up 20.4% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for RadNet?For RadNet, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -100.00%.

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that RadNet will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that RadNet would post earnings of $0.19 per share when it actually produced earnings of $0.23, delivering a surprise of +21.05%.

Over the last four quarters, the company has beaten consensus EPS estimates two times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

RadNet doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAmong the stocks in the Zacks Medical - Outpatient and Home Healthcare industry, Elanco Animal Health Incorporated (ELAN - Free Report) , is soon expected to post earnings of $0.34 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of -8.1%. This quarter's revenue is expected to be $1.28 billion, up 7.5% from the year-ago quarter.

Over the last 30 days, the consensus EPS estimate for Elanco Animal Health has been revised 0.4% down to the current level. Nevertheless, the company now has an Earnings ESP of -1.16%, reflecting a lower Most Accurate Estimate.

This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that Elanco Animal Health will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

RadNet (RDNT) has caught the attention of investors following its Q1 earnings report released today. Although the diagnostic imaging company reported a larger-t

RadNet, Inc. (RDNT) Q1 2026 Earnings Call Transcript

LOS ANGELES, May 28, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of over 440 outpatient imaging centers and a premier developer of radiology digital health solutions, today announced it will host a free webinar for patients and the general public on Saturday, June 13, 2026, in recognition of National Men’s Health Month. The event will feature presentations by radiologists on three of the most significant health conditions affecting American men today: coronary artery disease, prostate cancer and lung cancer.

The clinical case for increased attention to men's health is well established. Heart disease remains the leading cause of death for American men, with more than 52% of men over the age of 20 living with some form of cardiovascular disease.1 Prostate cancer — the second most commonly diagnosed cancer in men globally — affects 1 in 8 men, with more than 50% of risk tied to genetics.2 Lung cancer remains the leading cause of cancer-related death among men, yet only 28.1% of cases are diagnosed at an early stage, when treatment options are most effective.3 Across all three conditions, early detection is critical for improved outcomes. Men should talk to their physicians about potentially starting screening at 40 years for heart disease, 45 years for prostate cancer and 50 years for lung cancer.

The June 13 webinar will provide patients with accessible, physician-led education on risk factors, screening criteria and the role of diagnostic imaging in early detection. Attendees will also have the opportunity to participate in a live question and answer discussion with the physicians. Speakers include:

Michael G. Coords, MD, FSCCT, Medical Director, California, will present on coronary artery disease, offering a clinical overview of risk identification and the imaging tools available to detect disease before a cardiac event occurs.Randall Stenoien, MD, Medical Director, Texas, will present on advances in prostate MRI and AI for early detection of prostate cancer.Evan Kaminer, MD, FACR, Medical Director, New York, will present on low-dose CT for lung cancer screening and its benefits for high-risk asymptomatic patients. “Men's health is one of the most underdiscussed areas of preventive care, and we built this event specifically to close that gap,” said Gregory Sorensen, MD, Executive Vice President and Chief Strategy Officer, RadNet. “At RadNet, we believe that access to the latest information is just as important as access to the imaging technology itself. Early detection can save lives, and events like this are how we put that belief into action.”

RadNet operates more than 435 outpatient imaging centers across 11 states, providing patients with convenient access to advanced diagnostic imaging services, including cardiac CT, prostate MRI and low-dose lung CT screening. The company's AI-enhanced imaging technology and network of expert radiologists deliver accurate, timely results to support clinical decision-making and, where applicable, early intervention.

Event Details
The webinar is free to attend and open to all.

Date: Saturday, June 13, 2026Time: 10-11 a.m. PDT // 1-2 p.m. EDTRegister: www.radnet.com/webinars/mens-health About RadNet, Inc. 
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.  RadNet has a network of owned and/or operated outpatient imaging centers.  RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia.  In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally.  Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members.  Learn more at radnet.com. 

These presentations are provided for educational and informational purposes only and do not constitute medical advice, diagnosis or treatment recommendations. Clinical decisions should be based on the independent judgment of qualified healthcare professionals, taking into account the specific circumstances of each patient.

RadNet Media Contact 
Jane Mazur 
Senior Vice President, Corporate Communications 
+1 585-355-5978 
[email protected]  

References

      1)   Martin SS, et al., “2025 Heart Disease & Stroke Statistical Update Fact Sheet Males & Cardiovascular Diseases.” American Heart Association. January 2025.

      2)   “Key Statistics for Prostate Cancer.” American Cancer Society. January 2026.

What happenedAccording to an SEC filing dated May 14, 2026, Alpha Wave Global, LP reduced its RadNet (RDNT +0.07%) position by 63,147 shares in the first quarter. The estimated value of this trade is approximately $4.31 million based on the period’s average closing price. The fund’s quarter-end stake was 478,304 shares, with a reported value of $26.73 million.

What else to knowAlpha Wave Global, LP reduced its exposure to RadNet and the position now represents 3.38% of its 13F AUM.

Top holding after the filing:

NASDAQ:LENZ: $33.05 million (4.2% of AUM)As of May 13, 2026, RadNet shares were priced at $52.98, down 12.5% over the past year, underperforming the S&P 500 by 38.9 percentage points.

Company OverviewMetricValueRevenue (TTM)$2.14 billionNet Income (TTM)$-14.19 millionPrice (as of market close 2026-05-13)$52.98One-Year Price Change-12.47%Company SnapshotRadNet, Inc. is a leading provider of outpatient diagnostic imaging services in the United States, operating a large network of imaging centers and leveraging advanced technology to enhance radiology workflows. The company combines traditional imaging services with proprietary IT and artificial intelligence solutions, supporting both clinical efficiency and diagnostic accuracy. RadNet's scale, diversified service offerings, and ongoing investment in AI-driven innovation position it as a key player in the evolving medical diagnostics sector.

RadNet Inc. provides outpatient diagnostic imaging services, including MRI, CT, PET, nuclear medicine, mammography, ultrasound, and related procedures, as well as AI-driven software solutions for radiology. It operates a network of imaging centers and generates revenue primarily through patient imaging services and the development and sale of diagnostic imaging IT systems and AI products.

RadNet Inc. serves referring physicians, healthcare systems, and patients across multiple U.S. states, focusing on outpatient care and enterprise imaging solutions.

What this transaction means for investorsRadNet combines one of the country’s largest outpatient imaging networks with DeepHealth, its AI-enabled radiology workflow and screening platform. The imaging-center business remains the foundation, driven by patient volume, demand for advanced imaging, health-system partnerships, and center-level efficiency. DeepHealth adds a higher-growth digital layer, but it still has to prove that rapid revenue growth can turn into scalable profit.

RadNet’s first quarter results reinforce the investment case for its imaging network. Revenue increased 22.1% to $575.6 million, and adjusted EBITDA rose 36.3% to $63.3 million, driven by higher advanced imaging volumes across MRI, CT, and PET/CT. Digital Health’s ARR grew to $96.9 million, though segment profitability declined due to infrastructure investments supporting a larger sales pipeline.

In the near term, investors should focus on RadNet’s execution in imaging. Sustained growth depends on advanced imaging volume, center productivity, and health-system partnerships. The longer-term opportunity is where DeepHealth becoming a larger recurring-revenue contributor without requiring disproportionate investment from the core imaging business.

SOMERVILLE, Mass., June 10, 2026 (GLOBE NEWSWIRE) --  DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced the launch of Reporting Pro, a next-generation AI-powered solution designed to transform the way radiologists generate clinical reports and findings for their referring physicians.

Reporting Pro was introduced at RSNA 2025 and is now available for commercial deployment. Reporting Pro includes capabilities that bring speech recognition, AI-generated clinical findings, measurements, AI-generated impressions, quality assurance and structured reporting into one seamless workflow.

“Radiology is entering a new era where AI supports the diagnostic journey from image analysis to reporting. Reporting Pro is a critical step forward, bringing intelligence into the reporting workflow so radiologists can focus on review and refinement, rather than manual documentation,” said Madhu Jahagirdar, Business and Product Leader, Enterprise Imaging, DeepHealth.

As imaging volumes continue to rise, radiology demand is expected to outpace workforce capacity. Radiologist shortage is projected to reach about 15% by 2029 in the United States,1 and approximately 40% by 2030 in certain European countries.2 Reporting remains one of the most time-intensive and cognitively demanding steps for radiologists, creating a crucial opportunity to help them work more efficiently and consistently.

Reporting Pro automates high-volume reporting tasks with key capabilities including:

Clinical AI integration: Reporting Pro integrates clinical AI findings and measurements from FDA-cleared and CE-marked DeepHealth and third-party AI tools into the reporting workflow, enabling clinically relevant results to flow directly into structured report creation.Generative AI-powered reporting: Reporting Pro uses generative AI to help organize findings and generate draft impressions. The platform adapts based on physician feedback to better support how findings are summarized and structured, helping accelerate reporting while maintaining a high level of clinical quality.
Fast migration, deployment and adoption: Reporting Pro integrates with existing workflows. The solution supports migration of existing templates and reporting preferences from legacy reporting systems, enabling radiologists to maintain familiar workflows while adopting a more intelligent, AI-native reporting experience.Streamlined and automated reporting workflow: Reporting Pro connects speech recognition, clinical AI findings, measurements, AI-generated impressions, quality assurance and structured reporting capabilities into one unified experience. With integration of DeepHealth’s native clinical AI solutions, radiologists can review AI-supported draft content, refine it as needed and finalize reports within a connected reporting environment without any manual data transfer. Reporting Pro is being deployed across RadNet at scale, providing real-world validation of its capability to support faster, consistent reporting across high-volume clinical environments. The first set of external customers for Reporting Pro have also been contracted, with deployments going live within the next quarter.

“With Reporting Pro, a structured report is already waiting when I open a case with findings populated, measurements in place and a preliminary report drafted.  That significantly reduces reporting times, translating directly to faster turnaround times for patients and referring physicians who rely on receiving reports on a timely basis in order to make critical treatment decisions,” said Dr. Jason Sinner, Radiologist and Medical Director, RadNet.

Reporting Pro is designed to integrate with any existing picture archiving and communication system (PACS) and radiology information system (RIS). When deployed together with DeepHealth’s Diagnostic Suite,3 the solutions deliver a seamless reporting experience, connecting image management, AI findings, workflow orchestration and reporting. This helps route, prioritize, review and report cases more efficiently.

Reporting Pro is commercially available in the United States and the United Kingdom, with plans to release it in Australia, South Africa and select European markets by the end of the year. The platform is available across all imaging modalities, including X-ray, Ultrasound, CT, PET/CT and MRI.

DeepHealth will demonstrate Reporting Pro alongside its enterprise informatics portfolio of solutions at the Society of Imaging Informatics in Medicine (SIIM) Annual Meeting 2026 at booth #105-107.

About DeepHealth  
DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for RadNet’s Digital Health segment.  DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging.  DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, musculoskeletal, neuro, prostate and thyroid health.  At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow.  Thousands of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable and more efficient disease detection, including in large-scale cancer screening programs.  DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. Learn more at deephealth.com. 

About RadNet, Inc. 
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.  RadNet has a network of owned and/or operated outpatient imaging centers.  RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia.  In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally.  Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members.  Learn more at radnet.com. 

Forward Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding our technology’s ability to stage-shift disease through proactive, timely intervention and discussions regarding our product features. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet, nor any of its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the technology. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes, and other risks and uncertainties described in the “Risk Factors,” “Management’s Discussion and Analysis,” and other sections of our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

DeepHealth Media Contact
Andra Axente
Director of Communications
+31614440971
[email protected]

RadNet Media Contacts 
Jane Mazur 
Senior Vice President, Corporate Communications 
+1 585-355-5978 
[email protected]

Mark Stolper
Executive Vice President and Chief Financial Officer
+1 310-445-2800

References

Health Resources and Services Administration. "Workforce Projections." National Center for Health Workforce Analysis, n.d., data.hrsa.gov/topics/health-workforce/nchwa/workforce-projections. Accessed Sept 2025.Royal College of Radiologists Clinical Radiology Census 2024/25.Diagnostic Suite comprises multiple applications, including DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Any claims made about Diagnostic Suite may reference claims associated with its individual components. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/36e18576-8f41-44a5-9d1c-cf1c7309d34a

DeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology Reporting New solution integrates speech recognition, clinical AI findings, measurements, AI-generated impres...

On June 10, 2026, RadNet Inc RDNT shares rose 3.5% today, trading at $58.16. The stock has seen a 52-week range between $50.76 and $85.84, indicating significant volatility. Here are some key points regarding the current valuation of RadNet:

GF Value™ verdict: The current price of $58.16 is 12.1% below the GF Value™ of $66.18.GF Score™: RadNet has a strong GF Score™ of 80/100.Most notable signal: Insider activity shows that insiders sold $1.9 million worth of shares in the last three months, with no buying reported. Is RDNT Overvalued or Undervalued? Based on the GF Value™ assessment, RadNet is currently considered undervalued, with a price of $58.16 compared to an estimated fair value of $66.18. This provides a margin of safety of 12.1%, suggesting that there could be upside potential should the company's performance align more closely with its intrinsic value. The GF Valuation label indicates that RadNet is modestly undervalued, which presents an opportunity for investors willing to consider the inherent risks involved.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. While the undervaluation could be seen as an opportunity, potential investors should remain cautious, especially considering the company's recent stock performance and other fundamental indicators.

How Does RDNT's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 117.5x 114.0x RadNet's current forward P/E of 117.5x is slightly above its 5-year median P/E of 114.0x, indicating that the stock is trading at a premium relative to its historical valuation. This analysis aligns with the GF Value™ verdict of being undervalued, suggesting that while the stock may be considered high on a P/E basis, the overall valuation remains attractive when compared to its intrinsic value estimation.

What Does RDNT's GF Score™ Tell Us? Metric Rating GF Score™ 80/100 Financial Strength 4/10 Profitability 6/10 Growth 8/10 Valuation 10/10 Momentum 5/10 The GF Score™ of 80/100 indicates that RadNet is considered a strong investment based on its fundamental characteristics. The strongest area is its Valuation rank of 10/10, while the weakest area is its Financial Strength rank of 4/10. The growth potential is also notable with a rank of 8/10, showing that the company has avenues for further development, despite some concerns regarding its financial stability.

What Are Insiders Doing with RDNT Stock? In recent months, insiders have sold $1.9 million worth of RadNet stock, indicating a lack of confidence in the current price levels or future performance. The absence of any insider buying during this period raises further questions about the company's outlook from those closest to the business. This pattern can suggest that insiders may believe the stock is appropriately valued or could be overvalued at its current price.

What This Means for Investors Based on the GF Value™ analysis, RadNet Inc RDNT is currently undervalued with a margin of 12.1%, suggesting potential for price appreciation. However, investors should consider the mixed signals from insider activity and the company's financial strength before making any decisions.

For the complete analysis, visit the RadNet Inc RDNT stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is RDNT's GF Score™?

RadNet's GF Score™ is 80/100, indicating a strong investment based on its fundamental characteristics and potential for long-term returns.

Is RDNT overvalued or undervalued?

Based on the GF Value™ assessment, RadNet is currently undervalued by 12.1%, suggesting potential for price appreciation.

What is RDNT's P/E ratio?

RadNet's forward P/E ratio is currently 117.5x, which is above its historical median of 114.0x, indicating a premium valuation compared to its past performance.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].